Core Viewpoint - Rongchang Biopharmaceutical (09995) has signed an exclusive licensing agreement with AbbVie for its new dual-specific antibody drug RC148, targeting PD-1/VEGF, which will provide significant financial benefits to the company upon regulatory approval [1] Group 1: Agreement Details - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 outside of Greater China [1] - Upon regulatory approval, the company will receive an upfront payment of $650 million [1] - The company is eligible for up to $4.95 billion in milestone payments related to development, regulatory, and commercialization achievements [1] Group 2: Financial Implications - The agreement includes tiered royalties on net sales outside of Greater China, which are expected to be in double digits [1] - The total potential milestone payment amount remains uncertain as it is contingent upon meeting specific conditions [1]

本公告由榮昌生物製藥（煙台）股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則（「上市規則」）第13.09(2)條及證券及期貨條例（香港法例第571 章）第XIVA部項下的內幕消息條文（定義見上市規則）作出。 協議概述 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年1月12日（交易時段後）， 本公司與艾伯維集團控股公司（以下簡稱「艾伯維」）就RC148簽署獨家授權許可協 議（以下簡稱「協議」）。RC148是本公司研發的一款新型靶向PD-1/VEGF的雙特異 性抗體藥物。根據協議，艾伯維將獲得RC148在大中華區以外地區的（以下簡稱 「合作範圍」）的開發、生產和商業化的獨家權利。協議經相關監管批准生效後， 本公司將收到6.5億美元的首付款，並有資格獲得最高達49.5億美元的開發、監管 和商業化里程碑付款，以及在大中華區以外地區淨銷售額的兩位數分級特許權使 用費。協議中所約定的里程碑付款需要滿足一定的條件，本公司最終可實現的里 程碑付款金額尚存在不確定性。 本次交易已經董事會審議通過，無需提交股東會審議。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Insights - The biopharmaceutical sector experienced a rise of 0.61% on January 7, with Rongchang Biopharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4085.77, up 0.05%, while the Shenzhen Component Index closed at 14030.56, up 0.06% [1] Stock Performance - Rongchang Biopharmaceutical (688331) closed at 91.24, with a significant increase of 11.13%, and a trading volume of 129,800 shares, amounting to 1.134 billion yuan [1] - Other notable performers included Buyuan Biopharmaceutical (688765) with a closing price of 78.16, up 8.14%, and Aidi Pharmaceutical (688488) at 17.45, up 6.73% [1] - The overall trading volume and turnover for the biopharmaceutical sector indicated strong investor interest, with Rongchang Biopharmaceutical leading in both metrics [1] Capital Flow - The biopharmaceutical sector saw a net inflow of 158 million yuan from institutional investors, while retail investors experienced a net outflow of 163 million yuan [2] - The data indicates a mixed sentiment among different investor types, with institutional investors showing confidence in the sector [2][3] Individual Stock Capital Flow - Rongchang Biopharmaceutical had a net inflow of 128 million yuan from institutional investors, while retail investors showed a net outflow of approximately 50 million yuan [3] - Other companies like Ganli Pharmaceutical (603087) and Junshi Biosciences (688180) also experienced net inflows from institutional investors, indicating a trend of institutional support for select stocks within the sector [3]

港股创新药板块尾盘持续拉升，荣昌生物涨超13%，泰格医药、凯莱英涨超9%，药明生物、信达生物 涨超5%。 ...

Core Viewpoint - Rongchang Biopharma (09995) experienced a significant stock increase of over 11%, reaching HKD 90.15 with a trading volume of HKD 577 million, following the announcement of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 in treating non-small cell lung cancer [1] Group 1: Clinical Research and Drug Development - The clinical research data for RC148, both as a monotherapy and in combination therapy, demonstrated outstanding clinical efficacy and manageable safety, achieving a dual-pathway breakthrough [1] - Rongchang Biopharma's two innovative drugs have successfully been included in the 2025 National Medical Insurance Drug List for four indications [1] Group 2: Commercialization and Market Position - According to Zhongtai Securities, Rongchang Biopharma is accelerating its commercialization capabilities and is rapidly approaching the breakeven point through efficient operations and targeted investments [1] - The company’s drug, Vidisicimab, is proposed to be included as a breakthrough therapy for a new indication, in combination with trastuzumab and toripalimab for first-line treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma, which would mark its fourth breakthrough therapy designation if approved [1]

具体内容详见公司于2025年12月16日、2025年12月23日在上海证券交易所网站（www.sse.com.cn）披露 的《荣昌生物关于以集中竞价交易方式回购股份的预案》（公告编号：2025-055）、《荣昌生物制药 （烟台）股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号：2025-058）。 二、回购股份的进展情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）于2025年12月15日召开第二届董事会第三十二 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。同意公司使用自有资金 和/或自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额 不低于人民币2,000万元（含）且不超过人民币4,000万元（含），回购的股份将在未来合适的时机用于 员工持股计划或股权激励，回购价格不超过人民币95元/股（含），回购股 ...

Core Viewpoint - Rongchang Biologics (688331.SH) has announced that as of December 31, 2025, the company has not yet initiated any share buybacks and will implement buybacks opportunistically based on market conditions [1] Summary by Category - **Company Actions** - The company has not started any share repurchase program as of the end of 2025 [1] - The implementation of the buyback will depend on market conditions during the repurchase period [1]

Core Viewpoint - Rongchang Biologics (09995) has announced that as of December 31, 2025, the company has not yet initiated any share buybacks [1] Group 1 - The company plans to implement share buybacks opportunistically based on market conditions during the buyback period [1] - The company will fulfill its information disclosure obligations in a timely manner regarding the progress of the share buyback [1] - The progress of the buyback will comply with legal regulations and the company's buyback plan requirements [1]

荣昌生物(09995)发布公告，截至2025年12月31日，公司尚未开始股份回购。公司将在回购期限内根据 市场情况择机实施回购，并根据回购股份事项进展情况及时履行信息披露义务，上述回购进展符合法律 法规的规定及公司回购方案的要求。 ...